Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus SP1
- Development stage
- Phase 2
- Lead developer
- 2E Science
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
*Lactobacillus rhamnosus* SP1 is a specific probiotic strain of the species *Lactobacillus rhamnosus* that has been extensively studied for its therapeutic potential in oral health and dermatology. In dental applications, it is used as an adjunct to scaling and root planing (SRP) for conditions such as chronic periodontitis and gingivitis, and it is incorporated into milk to prevent dental caries in children. The strain functions by modulating the oral microbiota, inhibiting the colonization of periodontal pathogens through competitive exclusion, and dampening local inflammatory responses. Beyond oral health, systemic administration of *L. rhamnosus* SP1 has been shown to improve adult acne by modulating the gut-skin axis; specifically, it normalizes the skin expression of genes involved in insulin signaling, such as IGF1 and FOXO1. It is typically administered orally in the form of sachets, tablets, or supplemented food products.
- Other names
- L. rhamnosus SP1
02
Targets
FOXO1 (Forkhead box protein O1)IGF-1 (Insulin-like growth factor 1)
Beyond the preview
Go deeper on Lactobacillus rhamnosus SP1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus SP1.